SEC Filings

10-Q
MEDTRONIC PLC filed this Form 10-Q on 09/01/2017
Entire Document
 
Medtronic plc
Notes to Consolidated Financial Statements
(Unaudited)


Condensed Consolidating Statement of Cash Flows
Three Months Ended July 28, 2017
Medtronic Senior Notes and Medtronic Luxco Senior Notes

(in millions)
Medtronic plc
 
Medtronic, Inc.
 
Medtronic Luxco
 
Subsidiary Non-guarantors
 
Consolidating
Adjustments
 
Total
Operating Activities:
 
 
 
 
 
 
 
 
 
 
 
Net cash provided by (used in) operating activities
$
24

 
$
(355
)
 
$
86

 
$
982

 
$

 
$
737

Investing Activities:
 
 
 
 
 
 
 
 
 
 
 
Acquisitions, net of cash acquired

 

 

 

 

 

Additions to property, plant, and equipment

 
(68
)
 

 
(210
)
 

 
(278
)
Purchases of investments

 

 

 
(615
)
 

 
(615
)
Sales and maturities of investments

 

 

 
971

 

 
971

Net (increase) decrease in intercompany loans

 
431

 
(2,007
)
 
4,080

 
(2,504
)
 

Other investing activities, net

 

 

 
5

 

 
5

Net cash provided by (used in) investing activities

 
363

 
(2,007
)
 
4,231

 
(2,504
)
 
83

Financing Activities:
 
 
 
 
 
 
 
 
 
 
 
Acquisition-related contingent consideration

 

 

 
(3
)
 

 
(3
)
Change in current debt obligations, net

 

 
572

 
(3
)
 

 
569

Issuance of long-term debt

 

 

 
18

 

 
18

Payments on long-term debt

 

 

 
(8
)
 

 
(8
)
Dividends to shareholders
(625
)
 

 

 

 

 
(625
)
Issuance of ordinary shares
143

 

 

 

 

 
143

Repurchase of ordinary shares
(1,233
)
 

 

 

 

 
(1,233
)
Net intercompany loan borrowings (repayments)
1,691

 
10

 
1,373

 
(5,578
)
 
2,504

 

Intercompany dividend paid

 

 

 

 

 

Other financing activities

 

 

 
(2
)
 

 
(2
)
Net cash provided by (used in) financing activities
(24
)
 
10

 
1,945

 
(5,576
)
 
2,504

 
(1,141
)
Effect of exchange rate changes on cash and cash equivalents

 

 

 
45

 

 
45

Net change in cash and cash equivalents

 
18

 
24

 
(318
)
 

 
(276
)
Cash and cash equivalents at beginning of period

 
45

 
5

 
4,917

 

 
4,967

Cash and cash equivalents at end of period
$

 
$
63

 
$
29

 
$
4,599

 
$

 
$
4,691



38

X